Blocking the Hormone Receptors Modulates NLRP3 in LPS-Primed Breast Cancer Cells
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24054846 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Shaimaa Hamza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia. Hauptthemen laut MEDLINE: Breast Neoplasms, NLR Family, Pyrin Domain-Containing 3 Protein, Tamoxifen, Estrogen Receptor alpha. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Kazan Federal University Strategic Academic Leadership Program.
Abstract (Originalsprache)
NOD-like receptor protein 3 (NLRP3) may contribute to the growth and propagation of breast cancer (BC). The effect of estrogen receptor-α (ER-α), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) on NLRP3 activation in BC remains unknown. Additionally, our knowledge of the effect of blocking these receptors on NLRP3 expression is limited. We used GEPIA, UALCAN, and the Human Protein Atlas for transcriptomic profiling of NLRP3 in BC. Lipopolysaccharide (LPS) and adenosine 5′-triphosphate (ATP) were used to activate NLRP3 in luminal A MCF-7 and in TNBC MDA-MB-231 and HCC1806 cells. Tamoxifen (Tx), mifepristone (mife), and trastuzumab (Tmab) were used to block ER-α, PR, and HER2, respectively, on inflammasome activation in LPS-primed MCF7 cells. The transcript level of NLRP3 was correlated with ER-ɑ encoding gene ESR1 in luminal A (ER-α+, PR+) and TNBC tumors. NLRP3 protein expression was higher in untreated and LPS/ATP-treated MDA-MB-231 cells than in MCF7 cells. LPS/ATP-mediated NLRP3 activation reduced cell proliferation and recovery of wound healing in both BC cell lines. LPS/ATP treatment prevented spheroid formation in MDA-MB-231 cells but did not affect MCF7. HGF, IL-3, IL-8, M-CSF, MCP-1, and SCGF-b cytokines were secreted in both MDA-MB-231 and MCF7 cells in response to LPS/ATP treatment. Tx (ER-α inhibition) promoted NLRP3 activation and increased migration and sphere formation after LPS treatment of MCF7 cells. Tx-mediated activation of NLRP3 was associated with increased secretion of IL-8 and SCGF-b compared to LPS-only-treated MCF7 cells. In contrast, Tmab (Her2 inhibition) had a limited effect on NLRP3 activation in LPS-treated MCF7 cells. Mife (PR inhibition) opposed NLRP3 activation in LPS-primed MCF7 cells. We have found that Tx increased the expression of NLRP3 in LPS-primed MCF7. These data suggest a link between blocking ER-α and activation of NLRP3, which was associated with increased aggressiveness of the ER-α+ BC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
- Department of Fundamental Sciences, Faculty of Dentistry, Bursa Uludag University, Bursa 16059, Turkey.
ORCID-Profile: Shaimaa Hamza, Gulcin Tezcan
Förderung
- Russian Science Foundation
- Kazan Federal University Strategic Academic Leadership Program
Zitieren
APA
Hamza, S., Garanina, E. E., Alsaadi, M., Khaiboullina, S. F., & Tezcan, G. (2023). Blocking the Hormone Receptors Modulates NLRP3 in LPS-Primed Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054846
Vancouver
Hamza S, Garanina EE, Alsaadi M, Khaiboullina SF, Tezcan G. Blocking the Hormone Receptors Modulates NLRP3 in LPS-Primed Breast Cancer Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054846
BibTeX
@article{Hamza2023,
author = {Hamza, Shaimaa and Garanina, Ekaterina E and Alsaadi, Mohammad and Khaiboullina, Svetlana F and Tezcan, Gulcin},
title = {Blocking the Hormone Receptors Modulates NLRP3 in LPS-Primed Breast Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24054846}
}
EUVIMED